Keyphrases
Cisplatin Resistance
100%
Germ Cell Tumor
85%
Tumor Protein p53 (TP53)
57%
Poor Outcome
50%
Malignant Germ Cell Tumors
50%
Mediastinal Germ Cell Tumor
50%
Testicular Germ Cell Tumor
50%
Prepubertal Testis
37%
NCCIT
30%
TP53 mutant
20%
TP53 mutation
20%
Cisplatin
17%
Risk Stratification
14%
Resistance Mechanisms
14%
Resistant Disease
14%
Poor Clinical Outcomes
14%
Risk Classification
14%
Clinical Data
14%
Testis Function
12%
High Threat
12%
Preclinic
12%
Targeted Treatment
10%
Resistant Phenotypes
10%
Clinical Behavior
10%
Anatomical Localization
10%
Extragonadal
10%
Knockout Lines
10%
Platinum-based Chemotherapy
10%
Anatomical Location
10%
Testicle
10%
Resistant Clones
10%
Knock
10%
Mutant p53
10%
P53 Pathway
10%
Histology
10%
Tumor Cells
10%
Molecular Characteristics
7%
Tumor Cell Lines
7%
Resistance Level
7%
Adverse Outcomes
7%
Murine Double Minute 2 (MDM2)
7%
Tumor
7%
Copy number
7%
Collaborative Groups
7%
Genomic Profiling
7%
Overall Survival
7%
Treatment Modalities
7%
Teratoma
7%
Patient Samples
7%
Novel Treatments
7%
Medicine and Dentistry
Cisplatin
100%
Germinoma
100%
Mediastinal Germ Cell Tumor
21%
Protein P53
21%
Knock Out
14%
Risk Stratification
12%
Neoplasm
12%
Disease
12%
2102EP Cell Line
7%
Testes
7%
Targeted Therapy
7%
Cell Line
7%
Chemotherapy
7%
Systemic Therapy
6%
Progression Free Survival
6%
Dentigerous Cyst
6%
Cisplatin-Resistant Cell Line
6%
Adverse Outcome
6%
Germ Cell Tumor Cell Line
6%
Tumor Histology
6%
Germ Cell Cancer
6%
Endodermal Sinus Tumor
6%
Primary Tumor
6%
Proportional Hazards Model
6%
High Risk Population
6%
In Vitro
6%
Overall Survival
6%
Neuroscience
Cisplatin
100%
TP53
55%
Alkylating Antineoplastic Agent
50%
Cell Line
22%
P53
16%
Imatinib
12%
Etoposide
12%
Cyclophosphamide
12%
Vincristine
12%
Chemotherapy Regimens
12%
Doxorubicin
12%
Behavior (Neuroscience)
5%
In Vitro
5%
